Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for TCR2 THERAPEUTICS INC..
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 May 2023, 16:38.
Ansbert Gadicke - 22 May 2023 Form 4 Insider Report for TCR2 THERAPEUTICS INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 22 May 2023
- Net transaction value
- -$0.54
- SEC form
- 4
- Accepted by SEC
- 24 May 2023, 16:38:19 UTC
- Prior SEC filing
- 01 Aug 2022
- Next SEC filing
- 05 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for TCR2 THERAPEUTICS INC. on 24 May 2023.
Change
- Previous filing in this sequence was filed on 01 Aug 2022.
- Current net transaction value: -$0.54.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRR
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $131,919
- Shares
- +178,269
- Change %
- +91%
- Price
- $0.7400
- Shares after
- 374,171
- Date
- 22 May 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2
TCRR
transaction
Common Stock
Sale
- Transaction value
- $131,920
- Shares
- -70,170
- Change %
- -19%
- Price
- $1.88
- Shares after
- 304,001
- Date
- 22 May 2023
- Ownership
- See Footnote
- Footnotes
- F1, F2
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,854,963
- Date
- 22 May 2023
- Ownership
- See Footnote
- Footnotes
- F3
TCRR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,370,982
- Date
- 22 May 2023
- Ownership
- See Footnote
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TCRR
transaction
Derivative
Common Stock Warrant (Right To Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -42,761
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 22 May 2023
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 42,761
- Exercise price
- $0.7400
- Footnotes
- F1, F2
TCRR
transaction
Derivative
Common Stock Warrant (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -135,508
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 22 May 2023
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 135,508
- Exercise price
- $0.7400
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On May 22, 2023, MPM Asset Management LLC ("AM LLC") exercised warrants to purchase 178,269 shares of the Issuer's common stock for $0.74 a share. AM LLC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 70,170 of the warrant shares to satisfy the exercise price and issuing to AM LLC the remaining 108,099 shares.
Footnote F2
The shares are held by AM LLC. The reporting person is a member of AM LLC and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F3
The shares are held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. The reporting person is a managing director of BV LLC and a member of SunStates GP and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F4
The shares are held by UBS Oncology Impact Fund L.P. ("UBS Oncology"). BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. The reporting person is the managing partner of BioImpact and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.